MGI Tech filed disclosures that it will acquire two BGI Group spinouts—STOmics (spatial biology Stereo‑Seq commercialization) and CycloneSeq (BGI nanopore platforms)—for RMB 365.7 million (~$52.6 million). MGI said it will inject further capital into both businesses to support commercial expansion and technology transfers and expects the units to become profitable by 2026–2028. MGI framed the move as a step toward its "Seq All" strategy to offer integrated short‑ and long‑read sequencing solutions. The deal folds BGI‑developed spatial and nanopore technologies closer to a platform vendor (MGI), altering competitive dynamics in sequencing reagents and instruments. MGI will seek shareholder approval and has committed follow‑on investments to accelerate product commercialization and customer reach.